Drug Profile
RG 7356
Alternative Names: RG-7356; RO-5429083Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Chugai Biopharmaceuticals; Roche
- Developer Roche
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; CD44 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Solid tumours
Most Recent Events
- 01 Feb 2015 Roche completes a phase I trial for Acute myeloid leukaemia in France, Germany and Italy (NCT01641250)
- 30 Jan 2014 Discontinued - Phase-I for Acute myeloid leukaemia in Italy (IV)
- 30 Jan 2014 Discontinued - Phase-I for Solid tumours (late-stage disease, metastatic disease) in France and the Netherlands (IV)